This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|October 5, 2016
Multisorb to Build New Manufacturing Facility in India
Author(s)BioPharm International Editors
The company announced that it will build a new manufacturing facility at the GMR Aerospace Park at the Rajiv Gandhi International Airport in India.
Advertisement
On Oct. 4, 2016, Multisorb Technologies announced the construction of a new manufacturing facility in Hyderabad, Telangana, India. The new facility, made via foreign direct investment, will be located in the GMR Aerospace Park at the Rajiv Gandhi International Airport approximately 25 kilometers south of Hyderabad city center.
Approximately 4000 square meters in size, the facility will house Multisorb’s manufacturing processes in a cleanroom environment. The facility will be compliant to US FDA’s CGMP standards (21 CFR Parts 210-211). Laxmikant Khaitan, general manager of Multisorb Technologies India Pvt. Ltd., will lead the new Hyderabad site.
Multisorb plans to manufacture its DMF-supported products in its Hyderabad facility including StripPax desiccant/sorbent packets, IntelliSorb moisture regulating packets, and StabilOx oxygen absorbing packets. It expects to host customer quality system audits of the site during Q4-2017 and begin supplying Indian customers from the Hyderabad site in early Q1-2018.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5